Literature DB >> 8112360

Azithromycin resistance in Campylobacter jejuni and Campylobacter coli.

H Rautelin1, O V Renkonen, T U Kosunen.   

Abstract

The MICs of erythromycin, azithromycin and ciprofloxacin were determined for 60 human fecal isolates of Campylobacter. Of these, 30 strains selected on the basis of their resistance to erythromycin by disk diffusion were highly resistant to both erythromycin and azithromycin. Nine of these selected isolates were resistant to ciprofloxacin. The remaining 30 strains were non-selected, consecutive isolates of Campylobacter susceptible to erythromycin by disk diffusion and were shown to be two- to five-fold more susceptible to azithromycin than to erythromycin as determined by MIC testing.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8112360     DOI: 10.1007/bf02000410

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  13 in total

Review 1.  Mechanisms of antibiotic resistance in Campylobacter species.

Authors:  D E Taylor; P Courvalin
Journal:  Antimicrob Agents Chemother       Date:  1988-08       Impact factor: 5.191

2.  Quinolone resistance in campylobacter isolated from man and poultry following the introduction of fluoroquinolones in veterinary medicine.

Authors:  H P Endtz; G J Ruijs; B van Klingeren; W H Jansen; T van der Reyden; R P Mouton
Journal:  J Antimicrob Chemother       Date:  1991-02       Impact factor: 5.790

3.  Susceptibility of Campylobacter fetus subsp. jejuni to twenty antimicrobiol agents.

Authors:  M Walder
Journal:  Antimicrob Agents Chemother       Date:  1979-07       Impact factor: 5.191

4.  Prospective study of the etiology of diarrhea in adult outpatients and inpatients.

Authors:  H I Rautelin; O V Renkonen; C H von Bonsdorff; J Lähdevirta; T Pitkänen; A Järvinen; P Reinikainen; T U Kosunen
Journal:  Scand J Gastroenterol       Date:  1989-04       Impact factor: 2.423

5.  In-vitro activity of azithromycin against various Gram-negative bacilli and anaerobic bacteria.

Authors:  M D Kitzis; F W Goldstein; M Miégi; J F Acar
Journal:  J Antimicrob Chemother       Date:  1990-01       Impact factor: 5.790

6.  In vitro susceptibility of quinolone-resistant Campylobacter jejuni to new macrolide antibiotics.

Authors:  H P Endtz; M Broeren; R P Mouton
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993-01       Impact factor: 3.267

7.  In vitro susceptibilities of Campylobacter jejuni and Campylobacter coli to azithromycin and erythromycin.

Authors:  D E Taylor; N Chang
Journal:  Antimicrob Agents Chemother       Date:  1991-09       Impact factor: 5.191

8.  A demographic survey of campylobacter, salmonella and shigella infections in England. A Public Health Laboratory Service Survey.

Authors:  M B Skirrow
Journal:  Epidemiol Infect       Date:  1987-12       Impact factor: 2.451

9.  Susceptibility of clinical isolates of Campylobacter jejuni to twenty-five antimicrobial agents.

Authors:  L A Lariviere; C L Gaudreau; F F Turgeon
Journal:  J Antimicrob Chemother       Date:  1986-12       Impact factor: 5.790

10.  Bacteriostatic and bactericidal activities of 24 antimicrobial agents against Campylobacter fetus subsp. jejuni.

Authors:  R Vanhoof; B Gordts; R Dierickx; H Coignau; J P Butzler
Journal:  Antimicrob Agents Chemother       Date:  1980-07       Impact factor: 5.191

View more
  2 in total

1.  Antimicrobial susceptibilities of Campylobacter strains isolated from Finnish subjects infected domestically or from those infected abroad.

Authors:  Hilpi Rautelin; Antti Vierikko; Marja-Liisa Hänninen; Martti Vaara
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191

Review 2.  Ciprofloxacin. An updated review of its pharmacology, therapeutic efficacy and tolerability.

Authors:  R Davis; A Markham; J A Balfour
Journal:  Drugs       Date:  1996-06       Impact factor: 9.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.